All patients | p value | Propensity-matched Patients | p value | |||
---|---|---|---|---|---|---|
Single intercostal (n = 190) | Multi-intercostal (n = 432) | Single intercostal (n = 186) | Multi-intercostal (n = 186) | |||
Age(years) | 59.2 (8.7) | 61.3 (9.1) | 0.060 | 59.7 (8.3) | 59.9 (8.5) | 0.847 |
Sex | 0.221 | 0.834 | ||||
Male | 106 (55.8%) | 218 (50.5%) | 104 (55.9%) | 106 (57.0%) | ||
Female | 84 (44.2%) | 214 (49.5%) | 82 (44.1%) | 80 (43.0%) | ||
FEV1 (L) | 2.31 (0.43) | 2.38 (0.52) | 0.193 | 2.31 (0.43) | 2.31 (0.49) | 0.986 |
Smoking history | 0.245 | 0.832 | ||||
Yes | 74 (38.9%) | 156 (36.1%) | 74 (39.8%) | 72 (38.7%) | ||
No | 106 (61.1%) | 276 (63.9%) | 112 (60.2%) | 114 (61.3%) | ||
BMI(kg/m2) | 22.7 (2.8) | 23.1 (3.0) | 0.313 | 22.7 (2.8) | 23.4 (2.8) | 0.112 |
Tumor size (cm) | 2.1 (1.8) | 2.4 (1.7) | 0.238 | 2.1 (1.8) | 2.2 (1.5) | 0.787 |
Adenocarcinoma | 168 (88.4%) | 362 (83.8%) | 0.135 | 164 (88.2%) | 156 (83.9%) | 0.232 |
Location | 0.020 | 0.321 | ||||
LUL | 32 (16.8%) | 70 (16.2%) | 28 (15.1%) | 28 (15.1%) | ||
LLL | 24 (12.6%) | 98 (22.7%) | 24 (12.9%) | 32 (17.2%) | ||
RUL | 76 (40.0%) | 126 (29.2%) | 76 (40.9%) | 58 (31.2%) | ||
RML | 16 (8.4%) | 40 (9.3%) | 16 (8.6%) | 22 (11.8%) | ||
RLL | 42 (22.1%) | 98 (22.7%) | 42 (22.6%) | 46 (24.7%) | ||
Pathologic stage | 0.050 | 0.389 | ||||
I a | 140 (73.7%) | 278 (64.4%) | 136 (73.1%) | 133 (71.5%) | ||
I b | 6 (3.2%) | 28 (6.5%) | 6 (3.2%) | 8 (4.3%) | ||
II a | 2 (1.1%) | 16 (3.7%) | 2 (1.1%) | 8 (4.3%) | ||
II b | 20 (10.5%) | 46 (10.6%) | 20 (10.8%) | 14 (7.5%) | ||
III a | 18 (9.5%) | 60 (13.9%) | 18 (9.7%) | 20 (10.8%) | ||
III b | 4 (2.1%) | 4 (0.9%) | 4 (2.2%) | 3 (1.6%) |